Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ipsen SA
Digital Health Roundup: HIMSS, Cardio Conversations, ChatGPT And New FDA Guidances
In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb discusses how two medtech CEOs are and aren’t using ChatGPT in their businesses while Reed Miller talks about his “Cardio Conversations” podcast interviews with Quentin Blackford, CEO of iRhythm, and Rob Krummen, CEO of Vektor Medical. Washington, DC-based reporter Hannah Daniel reviews highlights from the HIMSS conference and the latest updates on FDA guidances.
News We’re Watching: AngelMed Becomes Avertix, 3M Layoffs, FDA Warns On COVID Test Use
This week, cardiac monitoring firm AngelMed announced its new name; Tempus nabbed FDA approval for its tumor profiling test; and iRhythm revealed that it’s been subpoenaed by the US Department of Justice.
Finger On The Pulse: The State Of Biopharma Leadership
In Vivo asked six biopharma figureheads to share their thoughts on the state of leadership in the life sciences space, exploring the qualities of a great leader, how recent years have shaped this role within the industry and the challenges ahead.
Minute Insight: Quest Diagnostics To Acquire Haystack Oncology For $300M In Cash
Quest Diagnostics will buy liquid biopsy start-up Haystack Oncology for a total of $450m with plans to launch a cancer-detection test in 2024.
- OTC, Consumer
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Albireo Pharma, Inc.
- Clementia Pharmaceuticals, Inc.
- Epizyme, Inc.
- Ipsen Bioscience, Inc.
- Tercica, Inc.
- Syntaxin Ltd.
- OctreoPharm Sciences GmbH
- Octagen Corporation
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.